| Date | Title | Description |
| 09.04.2025 | Empowering Change: The Rise of Visionary Leaders in Business | In the ever-evolving landscape of business, two leaders stand out, each carving a unique path in their respective industries. Natasha Miller, CEO of Entire Productions, and Omari Bouknight, CEO of Resonant Link Medical, exemplify the spirit... |
| 08.04.2025 | Resonant Link Medical Appoints Omari Bouknight as Chief Executive Officer | Omari Bouknight
Resonant Link Medical has appointed Omari V. Bouknight as CEO to lead the company's next phase of growth, leveraging his 20+ years of global experience commercializing medical technologies. Bouknight will drive the expansion... |
| 21.03.2025 | Cardiac Dimensions Raises $53M in Series E Financing | Cardiac Dimensions, a Kirkland, WA-based company which specializes in minimally invasive treatments for heart failure and functional mitral regurgitation (FMR), raised $53M in Series A funding.
The round was led by Ally Bridge Group, with p... |
| 06.01.2023 | Cardiac Dimensions Raises $35M in Series D Financing | Cardiac Dimensions, a Kirkland, WA-based developer of treatment modalities to address heart failure and related cardiovascular conditions, raised $35M in Series D funding.
The round was co-led by Horizon 3 Healthcare and an undisclosed stra... |
| 05.01.2023 | Cardiac Dimensions Closes $35M Series D Round |
KIRKLAND, WA, Cardiac Dimensions today announced it has closed a $35 million Series D financing round.
>> Click here for more funding data on Cardiac Dimensions
>> To export Cardiac Dimensions funding data to PDF and Excel, ... |
| 05.01.2023 |
Cardiac Dimensions raises $35M Series D for mitral contour system | The Carillon system. [Image courtesy of Cardiac Dimensions]Heart failure treatment developer Cardiac Dimensions announced today that closed a $35 million Series D financing round.
Kirkland, Washington-based Cardiac Dimensions develops minim... |
| 05.01.2023 | Cardiac Dimensions Raises $35 Million in Series D Financing | Funds Expected to Support Enrollment in U.S. Pivotal EMPOWER Trial and European Commercial Expansion for Carillon Mitral Contour System®. |
| 01.10.2020 | Seattle-area startup Cardiac Dimensions raises $17.5M for heart-valve repair device | Kirkland, Wash.-based Cardiac Dimensions raised a $17.5 million Series C round. The company will use the fresh cash to help sell its heart-valve repair device.
Founded in 2001, the Seattle-area medical device startup has developed a way to ... |
| 30.09.2020 | Cardiac Dimensions Raises $17.5M in Series C Financing | Cardiac Dimensions, a Kirkland, Wash.-based leader in the development of innovative, minimally invasive treatments for functional mitral regurgitation (FMR) in patients with heart failure, closed a $17.5m Series C financing.
All existing sh... |
| 06.03.2020 | Cardiac Dimensions Hires Gretchen Gary as VP of Global Therapy Development | KIRKLAND, Wash. /PRNewswire/ — Cardiac Dimensions®, a leader in the development of innovative, minimally invasive treatments for functional mitral regurgitation (FMR) in patients with heart failure (HF), today announced the hiring of Gretch... |
| 26.02.2020 | New Data Confirms Cardiac Dimensions’ Carillon® System Shows Favorable Long-Term Survival Rate In Patients | KIRKLAND, Wash. — Cardiac Dimensions, a leader in the development of innovative, minimally invasive treatments for functional mitral regurgitation (FMR) in patients with heart failure (HF), today announced the findings of a post hoc analysi... |
| 25.02.2020 | New Data Confirms Cardiac Dimensions' Carillon® System Shows Favorable Long-Term Survival Rate In Patients With Functional Mitral Regurgitation | Union Bulletin
By Cardiac Dimension
25 Feb 2020
KIRKLAND, Wash., Feb. 25, 2020 /PRNewswire/ -- Cardiac Dimensions, a leader in the development of innovative, minimally invasive treatments for functional mitral regurgitation (FMR) in patient... |
| 26.04.2019 | New Data Confirms Cardiac Dimensions’ Carillon® System Provides Acute Hemodynamic Efficacy in Patients with Functional Mitral Regurgitation | MANNHEIM, Germany – April 26, 2019 — Cardiac Dimensions, a leader in the development of innovative, minimally invasive treatments to address functional mitral regurgitation (FMR) in patients with heart failure (HF), presented new data confi... |
| 15.01.2019 | Cardiac Dimensions Appoints Carmelo Mastrandrea as Vice President of Sales | Medical Device Industry Expert to Spearhead European Sales of the Carillon Mitral Contour System |
| 18.10.2018 | Cardiac Dimensions Announces DRG Reimbursement Code for Carillon® Mitral Contour System® in Germany | With Reimbursement in Place and Positive Late-Breaking Data, Company Expects Continued Growth in Germany |
| 24.09.2018 | Cardiac Dimensions Announces Positive Late-Breaking Results for Blinded Clinical Trial of Minimally Invasive Heart Failure Treatment | In Randomized Blinded Study, the Carillon Mitral Contour System Catheter-Based Treatment Meets Endpoint for Reduction in Regurgitant Volume |
| 19.09.2018 | Cardiac Dimensions Announces the Randomization of its First Patient in the U.S. Pivotal Trial – The CARILLON Trial | KIRKLAND, Wash.- Cardiac Dimensions, Inc. a leader in the development of innovative, minimally invasive treatment modalities to address heart failure and related cardiovascular conditions, today announced the company has randomized its firs... |
| 26.04.2018 | Term Sheet — Thursday, April 26 | EURO $$$
Good morning, Term Sheet readers.
Paid Content You can't secure what you can't see From ExtraHop
Here are some key takeaways:
• In the first quarter of 2018, European investors deployed €4.4 billion across 571 deals, which is on pa... |
| 26.04.2018 | Cardiac Dimensions Raises $39M in Series B Financing | Cardiac Dimensions, a Kirkland, Wash.-based provider of development of minimally invasive treatments for patients with heart failure, closed a $39m Series B financing.
The round included new investor, Australia-based Hostplus, venture debt ... |
| 26.04.2018 | Cardiac Dimensions Announces $39 Million Series B Financing for Innovative Device to Treat Patients With Heart Failure | KIRKLAND, Wash.–(BUSINESS WIRE)– Cardiac Dimensions, a leader in the development of innovative, minimally invasive treatments for patients with heart failure, today announced the company has closed a $39 million Series B financing. The roun... |
| 26.04.2018 | Cardiac Dimensions Receives $39M Series B |
KIRKLAND, WA, Cardiac Dimensions today announced the company has closed a $39 million Series B financing.
>> Click here for more funding data on Cardiac Dimensions
>> To export Cardiac Dimensions funding data to PDF and Exce... |
| 26.03.2018 | Life-changing heart failure device brought closer home by $9.5m super investment | Hostplus
by Emily Martyn
26 March 2018
Hostplus has today announced a $9.5 million investment with Cardiac Dimensions, bringing the Carillon Mitral Contour System one step closer to saving Australians thousands on medical bills, weeks in re... |
| 10.09.2015 | Cost-Utility Analysis Projects CARILLON Mitral Contour System as a Cost Effective Treatment Option for Functional Mitral Regurgitation | KIRKLAND, Wash.–(BUSINESS WIRE)–The CARILLON® Mitral Contour System® is projected to be a cost-effective treatment option when compared to a typical regimen of optimal medical treatment (OMT), the present standard of care for functional mit... |
| 25.06.2015 | Cardiac Dimensions® Announces Initial Enrollments in REDUCE FMR Clinical Trial | Study is the FirstBlinded, Randomized Clinical Trial Evaluating a Mitral Valve Repair Device inPatients with Functional Mitral Regurgitation
(Kirkland, Wash.), June 25, 2015—Cardiac Dimensions® today announced that thefirst patients have be... |
| 13.03.2015 | Funding roundup - week ending 3/13/15 | Do, Zuroa, Lingua.ly, Greenhouse, Memebox, Elastica, Looker, Bento, VaporChat, ClassKick, mySugr
Seed stage
Meeting management startup Do raised a $2 million seed round from NEA, Dave Morin, Kevin Colleran, Mark Pincus, Aayush Phumbhra, Jim... |
| 11.03.2015 | Cardiac Dimensions Raises $15.2M | Cardiac Dimensions, a Kirkland, Washington-, Sydney, Australia- and Frankfurt, Germany-based medical device company developing novel interventional tools for the treatment of heart failure and the related condition of mitral valve regurgita... |
| 11.03.2015 | Cardiac Dimensions® Completes $43M Equity Financing | $15.2 Million Infusion from International Investors Rounds Out Financing; Funds Will Support Landmark Trial, Expand Commercial Operations
KIRKLAND, Wash., March 11, 2015 — Cardiac Dimensions® today announced the addition of $15.2 million to... |
| 08.10.2014 | Cardiac Dimensions Expands Financing to $28.5M |
KIRKLAND, WA, Cardiac Dimensions today announced the addition of $8.5 million to its previously announced financing.
>> Click here for more funding data on Cardiac Dimensions
>> To export Cardiac Dimensions funding data to P... |
| 07.10.2014 | Cardiac Dimensions Raises $8.5M in Funding | Cardiac Dimensions, a Kirkland, Washington; Sydney, Australia and Frankfurt, Germany-based developer of minimally invasive treatment modalities to address heart failure and related cardiovascular conditions, raised an additional $8.5m in fu... |
| 17.04.2014 | Cardiac Dimensions closes $20M equity round | Cardiac Dimensions said it raised $20 million from a syndicate of international investors for its Carillon mitral valve implant.
M.H. Carnegie & Co. and Lumira Capital led the round for Kirkland, Wash.-based Cardiac Dimensions, accordin... |
| 16.04.2014 | Cardiac Dimensions Completes $20M Financing | Cardiac Dimensions, Inc., a Kirkland, Washington-based developer of minimally invasive treatment modalities to address heart failure and related cardiovascular conditions, completed a $20m financing.
The round was led by M. H. Carnegie &... |
| 16.04.2014 | Rain in Seattle: Major Funding for Julep, Avvo, Cardiac Dimensions | Share Share on Facebook Share on Twitter LinkedIn Email Reprints
Three Seattle-area companies—Julep Beauty, Avvo, and Cardiac Dimensions—have announced significant new later-stage investments this week, totaling $87.5 million.
Add that to t... |
| 16.04.2014 | Cardiac Dimensions® Completes $20 Million Equity Financing | Funding Will Enable Initiation of Blinded Randomized Clinical Trial and Expanded Commercialization of CARILLON® Mitral Contour System®
(KIRKLAND, WA), April 16, 2014 — Cardiac Dimensions® Inc. today announced the completion of a $20 million... |
| 24.10.2011 | Tech Moves: Spoonemore named CEO of Dwellable; BigDoor adds staff, etc. | Spoonemore
Brenda Spoonemore, a former digital media executive at the NBA and a veteran of Starwave, has taken over the CEO duties at Seattle online vacation rental startup Dwellable. Spoonemore most recently led Atomic Moguls, a Seattle st... |
| 11.10.2011 | Cardiac Dimensions Announces First Patient Treated In TITAN II Clinical Trial | Learn More-External Link |
| 06.10.2011 | Light Sciences Stumbles, Cardiac Dimensions Gets EU OK, Immune Design Pockets $11M, & More Seattle-Area Life Sciences News | Share Share on Facebook Share on Twitter LinkedIn Email Reprints
This week had a smattering of pretty significant updates from companies that tend to (try anyway) to keep a pretty low profile.
—Seattle-based Immune Design, the developer of ... |
| 29.09.2011 | Cardiac Dimensions® Receives CE Mark Approval For Enhanced CARILLON® Mitral Contour System™ | Learn More-External Link |
| 04.05.2011 | Cardiac Dimensions® Announces Expansion of Clinical Reach with Initiation of Two New Clinical Studies of Its CARILLON® Mitral Contour System™ | Learn More-External Link |
| 26.01.2009 | Cardiac Dimensions, Fixer of Leaky Hearts, Edges Toward European Market and Pivotal U.S. Test | Share Share on Facebook Share on Twitter LinkedIn Email Reprints
Cardiac Dimensions has a dream of developing the first method for tightening up loose heart valves without requiring a surgeon to touch a scalpel. This year, the Kirkland, WA-... |
| 22.01.2009 | Cardiac Dimensions® Inc. Announces Achievement of Implant Target for TITAN™ Safety Study, January 2009 | Learn More-External Link |
| 27.11.2008 | Cardiac Dimensions® Inc. Receives 2008 Best of Kirkland Award | Learn More-External Link |
| 18.11.2008 | Cardiac Dimensions® Inc. Announces New Vice President of Research & Development | Learn More-External Link |
| 19.09.2008 | Cardiac Dimensions® Inc. announces Key Personnel Changes | Learn More-External Link |
| 19.12.2007 | Life sciences briefing: Wednesday, Dec. 19, 2007 | TODAY’S HEADLINES:
Gene-silencing developer Santaris raises €20M (PDF release)
Consumer-driven healthcare manager RedBrick Health prescribed $15M (release)
Cardiac Dimensions takes in $36M for heart-valve device (release)
TcLand Expressions... |
| 18.12.2007 | Cardiac Dimensions® Inc. Announces Closing of $35.5 Million Round of Financing. JJDC & Lumira Capital Co-Lead Round, Providing Funds to Be Used to Support FDA Clinical Trials of the CARILLON™ Mitr... | KIRKLAND, Wash.–(BUSINESS WIRE)–Cardiac Dimensions®, Inc. announced today it has closed $35.5 million in new venture capital. This Series D financing was co-led by Johnson & Johnson Development Corp. (JJDC) and Lumira Capital, and inclu... |
| - | Cardiac Dimensions | “We all know about the condition of heart failure. We just haven’t been able to treat it the right way—until now.” |
